Peak Pharmaceuticals, Inc. (PKPH) Financial Statements (2024 and earlier)

Company Profile

Business Address 14201 N. HAYDEN ROAD, SUITE A-1
SCOTTSDALE, AZ 85260
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2022
MRQ
9/30/2022
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments127,599261,1524085272,2702,991
Cash and cash equivalents127,599261,1524085272,2702,991
Prepaid expense2,750     
Total current assets:130,349261,1524085272,2702,991
Noncurrent Assets
Intangible assets, net (including goodwill)      35,000
Intangible assets, net (excluding goodwill)      35,000
Other undisclosed noncurrent assets      (35,000)
TOTAL ASSETS:130,349261,1524085272,2702,991
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities348,503249,337187,504172,612160,362170,676
Accounts payable224,548214,136162,532157,117153,176163,075
Accrued liabilities123,95535,20124,97215,4957,1867,601
Debt228,000283,00043,00043,00043,00025,000
Due to related parties35,000     
Other undisclosed current liabilities   20,00020,00020,000 
Total current liabilities:611,503532,337250,504235,612223,362195,676
Noncurrent Liabilities
Other undisclosed liabilities10,00055,000    
Total liabilities:621,503587,337250,504235,612223,362195,676
Equity
Equity, attributable to parent(491,154)(326,185)(250,096)(235,085)(221,092)(192,685)
Common stock7,8367,8367,8367,8367,8367,836
Additional paid in capital4,855,5664,855,5664,855,5664,855,5664,855,5664,855,566
Accumulated deficit(5,354,556)(5,189,587)(5,113,498)(5,098,487)(5,084,494)(5,056,087)
Total equity:(491,154)(326,185)(250,096)(235,085)(221,092)(192,685)
TOTAL LIABILITIES AND EQUITY:130,349261,1524085272,2702,991

Income Statement (P&L) (USD)

12/31/2022
TTM
9/30/2022
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Operating expenses(163,302)(68,721)(5,535)(5,684)(27,823)(44,987)
Operating loss:(163,302)(68,721)(5,535)(5,684)(27,823)(44,987)
Interest and debt expense(1,667)(7,368)(9,476)(8,309)(5,584)(1,239)
Loss from continuing operations:(164,969)(76,089)(15,011)(13,993)(33,407)(46,226)
Loss before gain (loss) on sale of properties:(164,969)(76,089)(15,011)(13,993)(33,407)(46,226)
Net loss:(164,969)(76,089)(15,011)(13,993)(33,407)(46,226)
Other undisclosed net income (loss) attributable to parent     5,000(5,001)
Net loss available to common stockholders, diluted:(164,969)(76,089)(15,011)(13,993)(28,407)(51,227)

Comprehensive Income (USD)

12/31/2022
TTM
9/30/2022
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Net loss:(164,969)(76,089)(15,011)(13,993)(33,407)(46,226)
Comprehensive loss, net of tax, attributable to parent:(164,969)(76,089)(15,011)(13,993)(33,407)(46,226)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: